Page 35 - JCTR-11-4
P. 35

Journal of Clinical and
            Translational Research                                                  Propranolol as a treatment for HCC



            67.  Simon TG, Duberg AS, Aleman S, et al. Lipophilic statins   glucose cotransporter 2-inhibitors on steatosis and fibrosis
               and risk for hepatocellular carcinoma and death in patients   in  patients  with  non-alcoholic  fatty  liver  disease  or
               with chronic viral hepatitis: Results from a nationwide   steatohepatitis and type 2 diabetes: A systematic review of
               Swedish population. Ann Intern Med. 2019;171(5):318-327.  randomized controlled trials. Medicina. 2023;59(6):1136.
               doi: 10.7326/M18-2753                              doi: 10.3390/medicina59061136
            68.  Memmott RM, Mercado JR, Maier CR, Kawabata S, Fox SD,   74.  Barone M, Viggiani MT, Losurdo G, Principi M, Di Leo A.
               Dennis PA. Metformin prevents tobacco carcinogen-  Systematic review: Renin-angiotensin system inhibitors
               induced lung tumorigenesis.  Cancer Prev Res (Phila).   in chemoprevention of hepatocellular carcinoma.  World J
               2010;3(9):1066-1076.                               Gastroenterol. 2019;25(20):2524.
               doi: 10.1158/1940-6207.CAPR-10-0055                doi: 10.3748/wjg.v25.i20.2524
            69.  Zi F, Zi H, Li Y, He J, Shi Q, Cai Z. Metformin and cancer: An   75.  Yi Z, Wang L, Tu X. Effect of vitamin D deficiency on liver
               existing drug for cancer prevention and therapy. Oncol Lett.   cancer risk: A systematic review and meta-analysis. Asian
               2018;15(1):683-690.                                Pac J Cancer Prev. 2021;22(4):991.
               doi: 10.3892/ol.2017.7412                          doi: 10.31557/APJCP.2021.22.4.991
            70.  Inzucchi SE, Lipska KJ, Mayo H, Bailey CJ, McGuire DK.   76.  Kunnumakkara AB, Hegde M, Parama D,  et al. Role of
               Metformin in patients with type 2 diabetes and kidney disease:   turmeric and curcumin in prevention and treatment of
               A systematic review. JAMA. 2014;312(24):2668-2675.  chronic diseases: Lessons learned from clinical trials. ACS
                                                                  Pharmacol Transl Sci. 2023;6(4):447-518.
               doi: 10.1001/jama.2014.15298
                                                                  doi: 10.1021/acsptsci.2c00012
            71.  Zhao X, Wang M, Wen Z, et al. GLP-1 receptor agonists:
               Beyond their pancreatic effects.  Front Endocrinol.   77.  Halegoua-DeMarzio D, Navarro V, Ahmad J,  et al. Liver
               2021;12:721135.                                    injury associated with turmeric-A growing problem:
                                                                  Ten cases from the Drug-Induced Liver Injury Network
               doi: 10.3389/fendo.2021.721135                     [DILIN]. Am J Med. 2023;136(2):200-206.
            72.  Wang L, Berger NA, Kaelber DC, Xu R. Association of      doi: 10.1016/j.amjmed.2022.09.026
               GLP-1  receptor  agonists  and  hepatocellular  carcinoma   78.  Ding Q, Li Z, Liu B, Ling L, Tian X, Zhang C. Propranolol
               incidence and hepatic decompensation in patients with   prevents  liver  cirrhosis  by  inhibiting  hepatic  stellate  cell
               type 2 diabetes. Gastroenterology. 2024;167(4):689-703.
                                                                  activation mediated by the PDGFR/Akt pathway.  Hum
               doi: 10.1053/j.gastro.2024.04.029                  Pathol. 2018;76:37-46.
            73.  Bica IC, Stoica RA, Salmen T, et al. The effects of sodium-     doi: 10.1016/j.humpath.2018.02.018


































            Volume 11 Issue 4 (2025)                        29                         doi: 10.36922/JCTR025080010
   30   31   32   33   34   35   36   37   38   39   40